Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perfusion therapy for extremity melanoma

A S Brown, M K Wallack, J T Horstmann

    Archives of Surgery (Chicago, Ill. : 1960)
    |September 1, 1976
    PubMed
    Summary

    Isolated perfusion with Melphalan offers an effective treatment for extremity melanomas, delivering cytotoxic drugs without systemic toxicity. This method shows a direct correlation between melanoma stage, treatment level, and prolonged patient survival.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction to: Elevated maternal C-reactive protein and autism in a national birth cohort.

    Molecular psychiatry·2025
    Same author

    Patient-centred outcomes.

    BJA education·2025
    Same author

    Infectious and immunogenetic factors in bipolar disorder.

    Acta psychiatrica Scandinavica·2017
    Same author

    Insights into the effects of metal nanostructuring and oxidation on the work function and charge transfer of metal/graphene hybrids.

    Nanoscale·2015
    Same author

    Development of on-line FTIR spectroscopy for siloxane detection in biogas to enhance carbon contactor management.

    Talanta·2015
    Same author

    CD8 subunit expression by plasmacytoid dendritic cells is variable, and does not define stable subsets.

    Mucosal immunology·2013

    Area of Science:

    • Oncology
    • Surgical Oncology
    • Pharmacology

    Background:

    • Malignant melanomas often appear on extremities, making them suitable for localized treatments.
    • Isolated chemotherapeutic perfusion allows high drug concentrations at the tumor site, minimizing systemic exposure and toxicity.

    Purpose of the Study:

    • To review the outcomes of isolated perfusion therapy for malignant melanomas.
    • To evaluate the efficacy of Melphalan as the primary chemotherapeutic agent in this setting.

    Main Methods:

    • Retrospective review of 20 patients treated with isolated perfusion between 1960 and 1973.
    • Melphalan (L-phenylalanine mustard) was the chemotherapeutic agent used for perfusion.
    • Analysis of survival rates based on prior surgical treatment and melanoma stage.

    Related Experiment Videos

    Main Results:

    • Of 20 patients, 11 had prior surgery; 3 remain alive (27-72 months).
    • Seven patients received perfusion as primary therapy; 4 remain alive (25-76 months).
    • A direct correlation was observed between melanoma stage/level and prolonged survival post-perfusion.

    Conclusions:

    • Isolated perfusion with Melphalan is a viable treatment for extremity melanomas.
    • The treatment demonstrates potential for prolonged survival, particularly when used as primary therapy.
    • Melanoma staging and perfusion level are critical factors influencing patient outcomes.